Physician profile
Cornelia B Daly
NPI 1174615389
$2,583.60
in general payments reported to CMS, 2019-2025
26 companies · $530 in 2025
The $530 reported for 2025 was more than what 76% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $237 · 2021: $430 · 2022: $270 · 2023: $384 · 2024: $276 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.89 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Amgen INC. | $340.73 | 2019-2025 | Evenity, Prolia |
| Coopersurgical, INC. | $177.21 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $174.19 | 2019-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Allergan, INC. | $173.57 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $146.30 | 2022-2025 | |
| Novo Nordisk INC | $120.22 | 2024 | Wegovy |
| Evofem Biosciences, INC. | $115.66 | 2021-2025 | Phexxi, Solosec, Phexx |
| Baxter Healthcare | $103.86 | 2022-2025 | Perclot |
| Sage Therapeutics, LLC | $79.19 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $67.09 | 2019-2023 | |
| Agile Therapeutics, INC. | $60.56 | 2021 | |
| Aspira Women'S Health INC | $53.33 | 2021 | |
| Therapeuticsmd, INC. | $53.16 | 2019-2021 | |
| Exeltis, USA INC. | $47.98 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $34.84 | 2023 | Proclaim, Eterna |
| Becton, Dickinson and Company | $33.14 | 2022-2024 | Bd Max System, Bd Max Instrument |
| Merck Sharp & Dohme LLC | $29.02 | 2019-2020 | |
| Myovant Sciences INC. | $28.73 | 2021-2022 | |
| Sanofi Pasteur INC. | $27.26 | 2024 | |
| Astellas Pharma US INC | $24.50 | 2024 | Veozah |
| Lilly USA, LLC | $22.47 | 2025 | Zepbound |
| Supernus Pharmaceuticals, INC. | $20.63 | 2025 | Qelbree |
| Ascend Therapeutics US, LLC | $17.84 | 2023 | |
| Neuronetics, INC. | $17.64 | 2023 | Neurostar Tms Therapy System |
| Lupin INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornelia Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.